Bullish!

Editor's Note: Our colleague Jeff Brown is well connected in biotech and government circles. During his recent research trip to the Pentagon, Jeff has learned about an unusual — and potentially highly lucrative — link between the U.S. military and a tiny biotech firm. We strongly encourage you to get the full story below...   Dear Reader, The biotech sector has been more generous to me and my readers than any other in recent years. A quick play on Dendreon doubled my money in just two months. The gene therapy small-caps I shared with subscribers went up 432% and 332%. And as of today, my gain on Intabio is 1,620%. Long-time readers will know I believe we're on the cusp of a major bull market in biotech. The mad scramble for a coronavirus vaccine and antiviral treatments only accelerated this trend. Right now, I'm tracking a situation bigger than any I mentioned earlier. Much bigger than anything else in my three-decade career. A tiny biotech company with the most powerful antibiotic in history. The drug is now in final, Phase 3 trials. Approval could come as early as this month. When approval comes, shares could go through the roof... Should you be invested? The answer is in this video. Sincerely, Jeff Brown Chief Technology Analyst © 2020 Legacy Research Group. All rights reserved. 55 NE 5th Avenue, Delray Beach, FL 33483, USA. To ensure our emails continue reaching your inbox, please add our email address to your address book. If you no longer wish to hear about this opportunity you can unsubscribe here.